NCRI 2018 | New thyroid cancer trials: questioning ablative radioiodine and exploring resensitization

Jonathan Wadsley

Jonathan Wadsley, MB, BChir, MA, MRCP, FRCR, of Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK, discusses the next steps in low risk thyroid cancer research. The ION trial (NCT01398085) is investigating whether radioiodine is necessary for low risk thyroid cancer, while resensitization is being explored for patients with radioiodine refractive disease in the SELIMETRY trial (EudraCT no. 2015-002269-47). This interview was recorded at the 2018 National Cancer Research Institute (NCRI) Cancer Conference, held in Glasgow, UK.

Share this video